ICU Medical, Inc. (NASDAQ:ICUI) Receives Average Rating of “Buy” from Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has received a consensus rating of “Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and three have issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $172.00.

A number of research firms have recently commented on ICUI. KeyCorp lifted their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research note on Tuesday. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a report on Wednesday, May 27th. Zacks Research raised shares of ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Finally, Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $158.77 on Wednesday. The company has a market cap of $3.97 billion, a P/E ratio of 85.82, a price-to-earnings-growth ratio of 2.20 and a beta of 0.76. ICU Medical has a 12-month low of $107.00 and a 12-month high of $162.85. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The company’s fifty day moving average is $142.12 and its two-hundred day moving average is $139.41.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The company had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company’s revenue was down 12.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities analysts expect that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. This represents a 23.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors have recently bought and sold shares of ICUI. Norges Bank bought a new position in shares of ICU Medical during the 4th quarter worth about $58,083,000. Kirr Marbach & Co. LLC IN increased its stake in ICU Medical by 18.4% in the first quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock valued at $5,702,000 after acquiring an additional 6,863 shares during the period. F m Investments LLC increased its stake in ICU Medical by 33.3% in the fourth quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after acquiring an additional 11,608 shares during the period. Thrivent Financial for Lutherans raised its position in ICU Medical by 1,604.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after purchasing an additional 285,648 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in ICU Medical by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock worth $387,313,000 after purchasing an additional 89,755 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.